Start-ups: Germany's biotech capital Munich is wooing Wall Street
In no other region are more biotech companies being founded than around Munich. The US bank JP Morgan senses big business – and wants to solve the industry's core problem.
JP Morgan, the largest US bank, has chosen Munich as a hub for its new life sciences business, aiming to channel billions of private wealth into Bavarian biotech firms. The bank's move is seen as a boost to the city's biotech ecosystem, which has produced successful companies like Tubulis, a cancer specialist sold to the US for $5 billion.
Munich is considered Germany's top biotech region, with a high concentration of universities, incubators, and investors, but it lacks sufficient capital to support start-ups. JP Morgan plans to tap into private wealth to fund biotech firms, with experts seeing potential for growth in the sector.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written; may contain errors — check the original.